Genelabs Technologies has received orphan drug designation for prasterone (Prestara), its investigational drug for lupus.
In The Pipeline
- Genelabs Technologies has received orphan drug designation for prasterone (Prestara), its investigational drug for lupus.
- Novartis has announced that its New Drug Application for deferasirox (Exjade) has been granted priority review by the FDA as a once-daily oral iron chelator for the treatment of chronic iron overload due to blood transfusions.
- Dendreon Corp. has completed enrollment in its Phase III PROTECT (P-11) clinical trial of APC8015 (Provenge) in men with nonmetastatic androgen-dependent (hormone-sensitive) prostate cancer.
- Dynavax Technologies Corp. has initiated a pivotal Phase III clinical trial of its hepatitis B vaccine.
- LAB International has initiated enrollment in a Phase I trial for its novel asthma product LAB CGRP (Calcitonin Gene-Related Peptide).
- Arginox Pharmaceuticals has begun patient enrollment in TRIUMPH, a pivotal Phase III trial of the drug, Tilarginine Acetate Injection (TAI), for the treatment of cardiogenic shock.
- Cell Genesys has initiated a second multicenter Phase III clinical trial of Gvax vaccine for prostate cancer in patients with metastatic hormone-refractory prostate cancer.
- Speedel announces the start of its Phase III study for SPP301, its once-a-day oral endothelin A receptor antagonist in the indication of diabetic nephropathy.
- ID Biomedical Corp. has been advised by the FDA’s Center for Biologics Evaluation and Research (CBER) that the company’s influenza virus vaccine (Fluviral) has been granted a fast-track designation.
- Keryx Biopharmaceuticalshas initiated its pivotal Phase III and Phase IV clinical program with oral sulodexide gelcap (KRX-101) for the treatment of diabetic nephropathy.
- CV Therapeutics has initiated a clinical program for CVT-6883, a selective, potent, and orally available A2B-adenosine receptor antagonist, intended to treat asthma with once-a-day dosing.
- Sangart has initiated a Phase II clinical trial involving MP4 (Hemospan), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.
- Cylene Pharmaceuticals has initiated a Phase I clinical trial for CX-3543, its lead candidate for the treatment of multiple cancers.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.